QUOTE AND NEWS
StreetInsider.com  May 1  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Haemonetics+Corp.+%28HAE%29+Tops+Q4+EPS+by+2c%3B+Guides+FY14+EPS+Above+Views/8292641.html for the full story.
StreetInsider.com  Apr 26  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Upgrades/Barrington+Research+Upgrades+Haemonetics+%28HAE%29+to+Outperform/8281473.html for the full story.
Benzinga  Apr 17  Comment 
Pharming Group NV and Santarus (NASDAQ: SNTS) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) to obtain marketing approval for RUCONEST® (recombinant human C1 esterase...
Forbes  Apr 15  Comment 
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Haemonetics Corp. (NYSE: HAE) was identified as having a larger market cap than the smaller end of the S&P 500, for example Apollo Group, Inc. (NASD:...
StreetInsider.com  Mar 25  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/BioCryst+Pharmaceuticals+%28BCRX%29+Initiates+Phase+1+Trial+of+BCX4161+for+HAE/8207855.html for the full story.
StreetInsider.com  Jan 30  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Haemonetics+Corp.+%28HAE%29+Tops+Q3+EPS+by+3c%3B+Reaffirms+Outlook/8041426.html for the full story.
Forbes  Jan 23  Comment 
Shares of Haemonetics (HAE) have been on the rise since it detailed its key growth initiatives at a health care conference on Jan. 9. It culminated with the company hitting its all-time high of $43.38 on Jan. 18.
StreetInsider.com  Jan 16  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ViroPharma+%28VPHM%29+Updates+on+Encouraging+Cinryze+Data+in+HAE/8011557.html for the full story.
Stock Blog Hub  Jan 14  Comment 
2013 is considered a landmark year for Haemonetics (HAE) based on several key growth factors, including entry in the $1.2 billion whole blood collection market with the acquisition of the transfusion medicine business of Pall Corp. We are also...
Benzinga  Dec 7  Comment 
BioCryst Pharmaceuticals (NASDAQ: BCRX) announced today that in response to recent events and an assessment of its assets, the Company is restructuring and implementing a focused strategy to advance its hereditary...




 
TOP CONTRIBUTORS

Haemonetics was founded in 1971 and became publicly owned in 1979. A division of American Hospital Supply Corporation, and then DuPont in 1985, the company completed its Initial Public Offering in 1991, with Du Pont divesting its remaining interest. The company is the market leader in developing and manufacturing blood collection and processing technology to help ensure a safe and adequate blood supply. The company manufactures automated systems and single use consumables used in blood donation, blood processing, and surgical salvage of blood. Haemonetics' customers are blood banks and plasma collectors, hospitals and hospital service providers. The American Red Cross is its largest customer. In 2004, the company reorganized into two product groups to address the blood donor and surgical patient markets. In Donor Products, the company offers automated plasma and platelet collection systems, as well as processing systems to freeze, thaw and wash red blood cells. The company also contract manufactures sterile I.V. solutions for pharmaceutical customers. In Patient Products, the company offers surgical blood salvage systems that are used to collect the patient's own blood that is then reused rather than lost. Haemonetics also markets data management systems through their 5D Information Systems subsidiary to promote efficient and compliant operations of blood collection vendors. The company operates in the U.S., Europe and Asia, including Japan. Haemonetics markets its products in more than 50 countries, using a direct sales force as well as some independent distributors, totaling 1,826 full time employees. In fiscal 2007, the company generated $449.6 million in revenues, with roughly 43% of revenues generated in the U.S. and the remainder internationally. Principally, Japan accounted for about 20% of fiscal 2007 revenues and Europe contributed about 28% to fiscal 2007 revenues.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki